



## **PRESS RELEASE**

### **Crucell secures important patent covering influenza vaccine production**

**Leiden, The Netherlands, April 3, 2007**– Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has been granted an important patent by the United States Patent and Trademark Office. The patent covers the manufacturing of influenza vaccines using Crucell's PER.C6<sup>®</sup> cell line technology. With this new patent Crucell considerably strengthened its PER.C6<sup>®</sup> patent portfolio in this field. The newly granted patent provides additional years of patent protection for the use of the PER.C6<sup>®</sup> technology in the influenza field.

In December 2003, sanofi pasteur and Crucell entered into an exclusive license agreement to further develop and commercialize new influenza vaccines based on Crucell's proprietary PER.C6<sup>®</sup> cell line technology. The agreement covers pre-pandemic, pandemic and inter-pandemic (seasonal) influenza vaccines. Sanofi pasteur initiated PER.C6<sup>®</sup>-based clinical studies for the influenza vaccine in September 2006.

#### **About Crucell**

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6<sup>®</sup> production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit [www.crucell.com](http://www.crucell.com).

#### **Forward-looking statements**

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).*

#### **For further information please contact:**

**Crucell N.V.**  
Leonard Kruimer  
Chief Financial Officer

**For Crucell in the US:**  
**Redington, Inc.**  
Thomas Redington



Tel. +31-(0)71-524 8722  
[Leonard.Kruimer@crucell.com](mailto:Leonard.Kruimer@crucell.com)

Tel. +1 212-926-1733  
[tredington@redingtoninc.com](mailto:tredington@redingtoninc.com)

Barbara Mulder  
Director Corporate Communications  
Tel: 31-(0) 71 524 8718  
[barbara.mulder@crucell.com](mailto:barbara.mulder@crucell.com)